Genetic changes in ATM and ATR/CHEK1 as prognostic indicators in cancer
The present invention relates to the discovery that, in human cancer, an 11q deletion of ATM together with an increase in ATR and CHEK1 expression correlates with resistance to ionizing radiation which could be overcome by inhibition of the ATR/CHEK1 pathway. It provides for methods of identifying patients unlikely to exhibit an adequate response to radiation therapy and/or chemotherapy who may benefit from ATR/CHEK1 pathway inhibition, as well as methods of treating said patients.
1. A method of identifying a patient suffering from a cancer which is likely to be refractory to radiation therapy comprising:
(i) identifying an 11q deletion in a patient sample considered to be representative of the cancer by a method selected from the group consisting of fluorescence in situ hybridization, quantitative microsatellite analysis, and loss of heterozygosity analysis;
(ii) identifying, in the patient sample, overexpression of a gene selected from the group consisting of ATR, CEK1, CCND1, and a combination thereof by a method selected from the group consisting of quantitative reverse transcriptase PCR, Western blot, and fluorescence in situ hybridization; and
(iii) identifying, in the patient sample, a decrease or absence of p53 expression and/or activity by a method selected from the group consisting of quantitative reverse transcriptase PCR and Western blot,
wherein an 11q deletion, overexpression of ATR, CHEK1, CCND1, or a combination thereof, and a decrease or absence of p53 expression and/or activity indicates that the cancer is likely to be refractory to radiation therapy and may benefit from inhibition of the ATR/CHEK1 pathway, wherein the cancer is selected from the group consisting of head and neck squamous cell carcinoma, breast carcinoma, ovarian carcinoma, lung carcinoma, multiple myeloma cancer, and prostate cancer.
2. A method of treating a patient suffering from a cancer selected from the group consisting of head and neck squamous cell carcinoma, breast carcinoma, ovarian carcinoma, lung carcinoma, multiple myeloma cancer, and prostate cancer, comprising (i) identifying the patient as being likely to benefit from inhibition of the ATR/CHEK1 pathway by a method comprising:
(a) identifying an 11q deletion in a patient sample considered to be representative of the cancer by a method selected from the group consisting of probe hybridization, fluorescence in situ hybridization, quantitative microsatellite analysis, PCR, quantitative DNA PCR, loss of heterozygosity analysis, array comparative genomic hybridization, and karyotype analysis,
(b) identifying, in the patient sample, overexpression of a gene selected from the group consisting of ATR, CHEK1, CCND1, and a combination thereof by a method selected from the group consisting of antibody-binding, probe hybridization, quantitative real-time PCR, quantitative reverse transcriptase PCR, Northern blot, immunohistochemistry, fluorescence in situ hybridization, and Western blot, and
(c) identifying, in the patient sample, a decrease or absence in p53 expression and/or activity by a method selected from the group consisting of antibody-binding, probe hybridization, quantitative real-time PCR, quantitative reverse transcriptase PCR, Northern blot, immunohistochemistry, fluorescence in situ hybridization, and Western blot, wherein an 11q deletion, overexpression of ATR, CHEK1, CCND1, or a combination thereof, and a decrease or absence in p53 expression and/or activity indicates that the cancer is likely to benefit from inhibition of the ATR/CHEK1 pathway; and
(ii) treating the patient with an inhibitor of the ATR/CHEK1 pathway.
3. The method of claim 1 , wherein the cancer is oral squamous cell carcinoma.
4. The method of claim 1 , wherein overexpression of ATR is identified.
5. The method of claim 1 , wherein overexpression of CHEK1 is identified.
6. The method of claim 1 , wherein overexpression of CCND1 is identified.
7. The method of claim 2 , wherein the cancer is oral squamous cell carcinoma.
8. The method of claim 2 , wherein overexpression of ATR is identified.
9. The method of claim 2 , wherein overexpression of CHEK1 is identified.
10. The method of claim 2 , wherein overexpression of CCND1 is identified.